Literature DB >> 22800940

SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years.

Z Touma1, D D Gladman, D Ibañez, M B Urowitz.   

Abstract

OBJECTIVES: To determine the frequency and the time to complete recovery identified by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the time to partial recovery identified by the SLEDAI-2K Responder Index 50 (SRI-50) in three laboratory systems over 10 years.
METHODS: This is a retrospective analysis of the data available from the Toronto Lupus Clinic over the last 10 years. Patients with SLEDAI-2K renal, immunological and hematologic active descriptors were identified. The percentage of descriptors with partial and complete recovery was studied at one year and over the study period. Descriptive analysis and the Kaplan-Meier estimator were applied to study the time to partial and complete recovery.
RESULTS: Of the 795 patients, 94% had an active system at some point during the study period. Partial recovery was shown in 66% of patients by SRI-50 for at least one descriptor over the study period. None of these partial findings identified would have been captured using SLEDAI-2K alone. The time to partial recovery identified by SRI-50 was shorter than the time to complete recovery identified by SLEDAI-2K.
CONCLUSION: The SRI-50 is a valid responder index derived form SLEDAI-2K and is very helpful in identifying clinically important improvement in active laboratory descriptors in an efficient time.

Entities:  

Mesh:

Year:  2012        PMID: 22800940     DOI: 10.1177/0961203312454344

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Top 10 things to know about lupus activity measures.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

2.  National systemic lupus erythematosus prospective cohort in Saudi Arabia: A study protocol.

Authors:  Ibrahim A Almaghlouth; Lena M Hassen; Hana S Alahmari; Asma Bedaiwi; Rana Albarrak; Maha Daghestani; Eman Alqurtas; Abdulaziz Alkhalaf; Mohammed Bedaiwi; Mohammed Omair; Sultan Almogairen; Hussein Alarfaj; Abdulrahman Alarfaj
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

Review 3.  Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.

Authors:  Jamal Mikdashi; Ola Nived
Journal:  Arthritis Res Ther       Date:  2015-07-20       Impact factor: 5.156

Review 4.  Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.

Authors:  Hanan Al Rayes; Zahi Touma
Journal:  Drug Des Devel Ther       Date:  2014-11-17       Impact factor: 4.162

Review 5.  Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Authors:  Zahi Touma; Dafna D Gladman
Journal:  Lupus Sci Med       Date:  2017-12-17

6.  The Expansion of Myeloid-Derived Suppressor Cells Is Associated with Joint Inflammation in Rheumatic Patients with Arthritis.

Authors:  Junqing Zhu; Shixian Chen; Lisheng Wu; Ran Wang; Songyuan Zheng; Di Zhao; Xiangyang Wang; Juan Li
Journal:  Biomed Res Int       Date:  2018-06-26       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.